Thursday, October 05, 2017 11:27:33 AM
Desiccare released its own statement about the association last week in which President and CEO Ken Blakenhorn said, “Quality is our basic principle,” and quoted Acology CEO Curt Fairbrother, “We’re very pleased with the way Desiccare stepped up and saw the possibilities that a partnership would offer.” This action comes only two weeks after Acology announced its deal with Desiccare Inc. to produce and sell 2-way humidity control packets using Acology’s MedX brand. It is anticipated that several more business associations will be reached in the near future. Ideal partners would complement Acology’s global reach and give the new product line added emphasis in the growing cannabis plant and edibles market.
This expansion is a continuation of Acology’s aggressive program, announced at the beginning of the year and rapidly continuing through the end of the quarter, of reaching into new spaces in the medical and recreational cannabis industry. The retiring of the third-party conversion note, announced 3 weeks ago, has enabled Acology to accelerate this planned expansion and has drawn the interest of other potential business partners. Strategic moves, such as the partnership deal with Desiccare Inc., changing Acology’s OTC status, placing new emphasis on the traditional medical industry and concluding additional partnership agreements with one or more prominent national and multi-national businesses are now the next steps in this expansion.
For investor or sales information please visit Acology Inc. and D&C Distributors online or by phone. The company is located in their production and distribution facility at 1620 Commerce St. Corona, California, 92880.
Acology trades on the OTC under the call letters ACOL. The company’s websites are www.Acologyinc.com for the hospice and palliative care industry and www.themedtainer.com for the recreational and medical marijuana industry. Orders for Acology products can be taken online and by phone. Custom orders are especially welcome. Please send all inquiries to info@acologyinc.com or call (844) ACOLOGY (844-226-5649). Ask for Jack Rein, National Services Director. Acology can also be accessed through Twitter and Instagram at @Acologyinc
This press release includes statements that are covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events they are subject to risks and uncertainties and actual results for fiscal year 2016 and beyond could differ materially from the company’s current expectations. Forward-looking statements are identified by such words as “anticipates”, “projects”, “expects”, “planned”, “intends” and “believes” “estimate” “targets” and other similar expressions that indicate trends and future events. It is understood that investment entails risk on the part of the investor and could result in the loss of some or all his or her investment.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM